Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A spectrum of genitourinary malformations ranging in severity from epispadias (E) and classical bladder exstrophy (CEB) to exstrophy of the cloaca (EC) as the most severe form. Depending on severity, the EEC may involve the urinary system, the musculoskeletal system, the pelvis, the pelvic floor, the abdominal wall, the genitalia and sometimes the spine and the anus.
Features include common findings: Vesicoureteral reflux, Abnormal abdominal wall morphology, Abdominal wall defect, and Cystocele; and sometimes findings: Urinary incontinence, Inguinal hernia, Bifid scrotum, and Renal duplication and others. 64 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 9 | Pelvic kidney, Renal agenesis, Urinary incontinence |
Biomarker and diagnostic research for exstrophy-epispadias complex has been reported in the published literature.
No approved treatments are currently available for exstrophy-epispadias complex. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for exstrophy-epispadias complex, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for exstrophy-epispadias complex. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Phenotype severity distribution: 4 common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for exstrophy-epispadias complex.
64 publications have been identified in PubMed for exstrophy-epispadias complex. Research spans Review / Meta-Analysis (23%), Case Report / Case Series (23%), and Clinical Trial Publication (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 15 | 23% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:42 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Digestive system |
4 |
Intestinal malrotation, Abnormal abdominal wall morphology, Abdominal wall defect |
Brain and nerves | 2 | Hydrocephalus, Abnormal brain morphology |
Bones and joints | 2 | Abnormal joint morphology, Abnormal skeletal morphology |
Head and neck | 2 | Microcephaly, Abnormality of the face |
Pregnancy and birth | 1 | Congenital hip dislocation |
Heart and blood vessels | 1 | Abnormal heart morphology |
Designated
Exclusivity End |
|---|
Designation Status |
|---|
Primary Human Satellite cell-derived muscle stem cells | Primary Human Satellite cell-derived muscle stem cells | MyoPax Denmark ApS | 2023 | — | Designated |
Gene therapy approaches for exstrophy-epispadias complex have been reported in the published literature.
View trials for exstrophy-epispadias complex
15 |
23% |
Clinical study results | 12 | 19% |
Laboratory research | 9 | 14% |
Disease patterns and progression | 8 | 13% |
Other research | 2 | 3% |
New treatment approaches | 2 | 3% |
Testing and diagnosis research | 1 | 2% |
Seibt J (2026). [PMID: 42034542](https://pubmed.ncbi.nlm.nih.gov/42034542/). *J Pediatr Urol*. [Epidemiology / Natural History]
Kalra S (2026). [PMID: 41562020](https://pubmed.ncbi.nlm.nih.gov/41562020/). *Indian journal of urology : IJU : journal of the Urological Society of India*. [Epidemiology / Natural History]
Onofre LS (2026). [PMID: 41390281](https://pubmed.ncbi.nlm.nih.gov/41390281/). *Journal of pediatric urology*. [Review / Meta-Analysis]
Kamran H (2026). [PMID: 41713335](https://pubmed.ncbi.nlm.nih.gov/41713335/). *Journal of pediatric urology*. [Epidemiology / Natural History]
Crigger CB (2026). [PMID: 42092585](https://pubmed.ncbi.nlm.nih.gov/42092585/). *J Pediatr Surg*. [Clinical Trial Publication]
Bonasoni MP (2026). [PMID: 41778963](https://pubmed.ncbi.nlm.nih.gov/41778963/). *Fetal and pediatric pathology*. [Basic Science / Preclinical]
Mansy M (2026). [PMID: 41664006](https://pubmed.ncbi.nlm.nih.gov/41664006/). *BMC surgery*. [Basic Science / Preclinical]
Chen L (2026). [PMID: 41033943](https://pubmed.ncbi.nlm.nih.gov/41033943/). *J Pediatr Urol*. [Other]
Yazawa O (2026). [PMID: 41891914](https://pubmed.ncbi.nlm.nih.gov/41891914/). *Congenit Anom (Kyoto)*. [Case Report / Case Series]
Taher H (2026). [PMID: 41998595](https://pubmed.ncbi.nlm.nih.gov/41998595/). *BMC Pediatr*. [Review / Meta-Analysis]